Pharmafile Logo

dual tasking

- PMLiVE

Study finds mixed vaccine schedules provide strong immune response against COVID-19

And AZ's Vaxzevria COVID-19 vaccine shows strong immune responses following a delayed second dose

AZ appoints Susan Galbraith as executive vice president, oncology R&D

Galbraith’s appointment into the role follows the passing of José Baselga earlier this year

- PMLiVE

Mental well-being is for life, not just awareness week

Helping people identify any issues that may be affecting their mental well-being is a great first step

- PMLiVE

Breakthrough therapy designated for Lilly’s investigational Alzheimer’s drug donanemab

The BTD is based on data from the phase 2 TRAILBLAZER-ALZ study in early symptomatic Alzheimer's patients

- PMLiVE

Understanding the authentic patient experience can redefine the success of your clinical trial before you design it

. Su contributes our experience are Origins that there is a willingness within the Pharmaceutical Industry to change attitudes towards clinical trial populations – making them less about academic and...

Origins – The Patient Focused Specialists

- PMLiVE

Lilly showcases tirzepatide type 2 diabetes data at ADA 2021

Company is planning to submit the full data package for tirzepatide to regulatory authorities by the end of 2021

- PMLiVE

Stick or twist? Looking at the patient experience as we emerge from the COVID pandemic

The pandemic has given us a glimpse (actually, more of a very long look) at an alternative way of receiving healthcare and engaging with the NHS. And that alternative fits...

Say Communications

- PMLiVE

Novo Nordisk reveals positive results at ADA 2021 for higher-dose Ozempic in type 2 diabetes

Ozempic 2 mg demonstrated a 2.2% reduction in blood sugar compared with a 1.9% reduction for those receiving Ozempic 1 mg

- PMLiVE

Stick or Twist? Healthcare brands in a (post) COVID-19 world

How have our perceptions of healthcare brands and our purchasing habits changed during the COVID-19 pandemic?

Say Communications

- PMLiVE

US pauses shipments of Eli Lilly’s COVID-19 antibody treatment due to variant concerns

Laboratory analyses found the therapy was not effective against variants first discovered in South Africa and Brazil

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links